Obsidian Therapeutics
Healthcare & Life Sci
Company overview
Obsidian Therapeutics develops cell therapies for cancer using engineered tumor-infiltrating lymphocytes, known as TILs. It builds these therapies on its own cytoDRIVE platform, a proprietary technology for engineering TIL cells. The company was founded in 2015. Obsidian Therapeutics is based in Cambridge, Massachusetts.
Obsidian Therapeutics has raised $330.5M across funding rounds. It went public on Nasdaq in August 2026 under the ticker OBX. For someone considering joining, this marks a shift from a private biotech to a newly public, commercially accountable company.
Currently, there are no job openings at Obsidian Therapeutics. Over the last 30 days, 0 jobs were added and 0 were removed. Obsidian Therapeutics is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Cambridge, United States